Symptom Map of Endocrine Therapy for Breast Cancer: A Scoping Review

被引:25
|
作者
Zhu, Yehui [1 ]
Cohen, Susan M. [1 ]
Rosenzweig, Margaret Q. [1 ]
Bender, Catherine M. [1 ]
机构
[1] Univ Pittsburgh, Sch Nursing, 415 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA
关键词
Aromatase inhibitors; Breast neoplasms; Scoping review; Signs and symptoms; Tamoxifen; AROMATASE INHIBITOR THERAPY; QUALITY-OF-LIFE; MUSCULOSKELETAL SYMPTOMS; POSTMENOPAUSAL WOMEN; RISK-FACTORS; TAMOXIFEN TREATMENT; SEXUAL DYSFUNCTION; HORMONAL-THERAPY; JOINT SYMPTOMS; RECALL PERIOD;
D O I
10.1097/NCC.0000000000000632
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Multiple symptoms associated with endocrine therapy have a detrimental impact on medication adherence and quality of life. Objective The purpose of this scoping review is to map the symptoms during endocrine therapy for breast cancer to provide implications for current practice and suggestions for future research. Methods The PubMed, CINAHL, and China Science Periodical Databases were searched to identify related studies published in English and Chinese languages. References of included articles were reviewed for additional eligible studies. Of the 2551 articles identified, 57 articles met inclusion criteria and were included in this scoping review. Results Evidence for the 16 most studied symptoms and 15 most prevalent symptoms were synthesized. Five key symptoms associated with endocrine therapy were identified, including joint/muscle pain, hot flashes, low sexual interest/desire, joint/muscle stiffness, and fatigue/lack of energy. Rarely studied but highly prevalent symptoms and other gaps in the symptom science during endocrine therapy for breast cancer were identified. Conclusion Nurses caring for women receiving endocrine therapy for breast cancer should assess the 5 key symptoms identified. There remain substantial gaps in the science related to the symptom experience during endocrine therapy for breast cancer. Future studies should focus on the domains of symptom intensity and distress, specific understudied symptoms, symptom clusters, and development of symptom assessment instruments specific to symptoms associated with endocrine therapy.
引用
下载
收藏
页码:E19 / E30
页数:12
相关论文
共 50 条
  • [41] Endocrine therapy of metastatic breast cancer
    Laura Rodríguez Lajusticia
    Miguel Martín Jiménez
    Sara López-Tarruella Cobo
    Clinical and Translational Oncology, 2008, 10 : 462 - 467
  • [42] Neoadjuvant endocrine therapy in breast cancer
    Beresford, M. J.
    Ravichandran, D.
    Makris, A.
    CANCER TREATMENT REVIEWS, 2007, 33 (01) : 48 - 57
  • [43] Endocrine Therapy in Early Breast Cancer
    Krauss, Katja
    Stickeler, Elmar
    BREAST CARE, 2020, 15 (04) : 337 - 346
  • [44] Update on endocrine therapy for breast cancer
    Buzdar, AU
    Hortobagyi, G
    CLINICAL CANCER RESEARCH, 1998, 4 (03) : 527 - 534
  • [45] Optimizing endocrine therapy for breast cancer
    Winer, EP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (08) : 1609 - 1610
  • [46] Endocrine therapy of early breast cancer
    Buchholz, S.
    Moegele, M.
    Ortmann, O.
    GYNAKOLOGE, 2012, 45 (08): : 603 - 607
  • [47] Resistance to endocrine therapy in breast cancer
    Junichi Kurebayashi
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 39 - 46
  • [48] Pharmacogenomics and Endocrine Therapy in Breast Cancer
    Hayes, Daniel F.
    Rae, James M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06) : 525 - +
  • [49] ENDOCRINE THERAPY FOR BREAST-CANCER
    SCHNURCH, HG
    GYNAKOLOGE, 1993, 26 (02): : 107 - &
  • [50] Pharmacogenomics of endocrine therapy in breast cancer
    James N Ingle
    Journal of Human Genetics, 2013, 58 : 306 - 312